Is Vaxart, Inc. (NASDAQ:VXRT) Stock Ready To Cross Above $10 This Month?
The recent developments in the company, makes Vasart Inc. a potential buy for the investors. Vaxart, Inc. (NASDAQ:VXRT) is a clinical-stage biotechnology company which engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The recent news of the company signing a world-wide exclusive licensing agreement with Altesa Biosciences Inc. allowing the latter to develop and commercialize Vaxart’sVapendavir antiviral is an important milestone in the company’s business.
The deal would provide Vaxartthe eligibility to receive up to $130 million in development and commercial milestones, as well as tiered royalties. Even the company’s Covid-19 vaccine candidate is also effective. This is based on the data showing that patients developed stronger T-cell responses than those who received the vaccines made by Moderna and Pfizer.
The company further provided evidence that another one of its vaccine candidates (a shot that is supposed to prevent the flu) showed analogouseffectiveness, immunogenicity and protection as Sanofi’s flu vaccine in a Phase 2 trial.Also, the company’s experienced management team on the helm increases the confidence of the investors in the business.
Thus, though the growth rate is not as expected, one cannot overlook the upcoming projects when investment is into consideration. Summing up, the analysts’ optimism about Vaxart makes me more upbeat on the shares and helps it move towards the path of profitability.
